Prot# ECOG PCO-RL: E2205 BM: A Phase II Study to Measure Response Rate and Toxicity of Neo-Adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients

Project: Research project

Project Details

Effective start/end date6/9/086/8/16


  • Frontier Science and Technology Research Foundation (PCOE22205BM-00-E2205)
  • ImClone Systems Incorporated (PCOE22205BM-00-E2205)